METHOD FOR TREATING A GD2-POSITIVE CANCER

摘要

A method of treating a newly diagnosed neuroblastoma in a patient by administering chimeric anti-GD2 antibody dinutuximab beta to the patient in combination with induction chemotherapy. The chimeric anti-GD2 antibody dinutuximab beta is administered at a cumulative dose of up to 500 mg/m2, and/or in a dose of up to 100 mg/m2 per cycle during one or more cycles of induction chemotherapy, and/or at a treatment density of up to 5 mg/m2/day.